- Home
- GNPX vs CEAD Comparison
GNPX vs CEAD Comparison
Compare GNPX & CEAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- CEAD
- Stock Information
- Founded
- GNPX 2009
- CEAD 2009
- Country
- GNPX United States
- CEAD United States
- Employees
- GNPX N/A
- CEAD N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- CEAD Industrial Machinery/Components
- Sector
- GNPX Health Care
- CEAD Industrials
- Exchange
- GNPX Nasdaq
- CEAD Nasdaq
- Market Cap
- GNPX 6.1M
- CEAD 6.9M
- IPO Year
- GNPX 2018
- CEAD N/A
- Fundamental
- Price
- GNPX $0.38
- CEAD $7.77
- Analyst Decision
- GNPX Strong Buy
- CEAD
- Analyst Count
- GNPX 1
- CEAD 0
- Target Price
- GNPX $10.00
- CEAD N/A
- AVG Volume (30 Days)
- GNPX 6.0M
- CEAD 22.9K
- Earning Date
- GNPX 05-13-2025
- CEAD 03-27-2025
- Dividend Yield
- GNPX N/A
- CEAD N/A
- EPS Growth
- GNPX N/A
- CEAD N/A
- EPS
- GNPX N/A
- CEAD N/A
- Revenue
- GNPX N/A
- CEAD $2,803,470.00
- Revenue This Year
- GNPX N/A
- CEAD N/A
- Revenue Next Year
- GNPX N/A
- CEAD N/A
- P/E Ratio
- GNPX N/A
- CEAD N/A
- Revenue Growth
- GNPX N/A
- CEAD N/A
- 52 Week Low
- GNPX $0.22
- CEAD $5.60
- 52 Week High
- GNPX $4.09
- CEAD $12.26
- Technical
- Relative Strength Index (RSI)
- GNPX 43.09
- CEAD 51.59
- Support Level
- GNPX $0.22
- CEAD $8.43
- Resistance Level
- GNPX $0.39
- CEAD $9.45
- Average True Range (ATR)
- GNPX 0.06
- CEAD 0.79
- MACD
- GNPX 0.00
- CEAD 0.08
- Stochastic Oscillator
- GNPX 31.23
- CEAD 72.30
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About CEAD CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.